Patents by Inventor Patrick M. Hughes

Patrick M. Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS
    Publication number: 20140086974
    Abstract: Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.
    Type: Application
    Filed: September 26, 2013
    Publication date: March 27, 2014
    Inventors: Cindy W. Wu, Michael R. Robinson, James A. Burke, Patrick M. Hughes
  • Intraocular pressure reduction with intracameral bimatoprost implants
    Patent number: 8673341
    Abstract: The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: March 18, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • ALPHA-2 AGONIST POLYMERIC DRUG DELIVERY SYSTEMS
    Publication number: 20140038972
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Application
    Filed: August 30, 2013
    Publication date: February 6, 2014
    Applicant: Allergan, Inc.
    Inventors: James N. Chang, Lon T. Spada, Wendy M. Blanda, Werhner C. Orilla, James A. Burke, Patrick M. Hughes
  • Biodegradable Intravitreal Tyrosine Kinase Implants
    Publication number: 20140031408
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: August 19, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Compositions and Methods for Localized Therapy of the Eye
    Publication number: 20140031298
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.
    Type: Application
    Filed: April 5, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Scott M. Whitcup, James A. Burke
  • Compositions and methods for the intraocular transport of therapeutic agents
    Patent number: 8637571
    Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: January 28, 2014
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Joan-En Chang-Lin
  • Hypotensive prostamide-containing biodegradable intraocular implants and related methods
    Patent number: 8637068
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: January 28, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • METHOD FOR DETERMINING OPTIMUM INTRAOCULAR LOCATIONS FOR DRUG DELIVERY SYSTEMS
    Publication number: 20140010823
    Abstract: A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 9, 2014
    Applicant: Allergan, Inc.
    Inventors: Michael R. Robinson, Joan-En Chang-Lin, Devin F. Welty, Patrick M. Hughes, Scott M. Whitcup
  • Sustained release intraocular implants and methods for preventing retinal dysfunction
    Patent number: 8609144
    Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton C. Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn
  • Tyrosine Kinase Microspheres
    Publication number: 20130330395
    Abstract: Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: July 8, 2013
    Publication date: December 12, 2013
    Inventors: Patrick M. Hughes, Christian Sarrazin, Elisabeth Rossi, Michele Boix
  • Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
    Patent number: 8591885
    Abstract: Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 26, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Patrick M. Hughes, Gerald W. Devries
  • Sustained release intraocular implants and methods for treating ocular vasculopathies
    Patent number: 8580292
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: November 12, 2013
    Assignee: Allergan, Inc.
    Inventors: Glenn T Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Method for determining optimum intraocular locations for drug delivery systems
    Patent number: 8571802
    Abstract: A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Joan-En Chang-Lin, Devin F. Welty, Scott M. Whitcup, Patrick M. Hughes
  • KINASE INHIBITORS
    Publication number: 20130267497
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 10, 2013
    Inventors: Lon T. Spada, Jane-Gou Shiah, Patrick M. Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods
    Publication number: 20130236557
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the ploymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: April 12, 2013
    Publication date: September 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF
    Publication number: 20130237602
    Abstract: Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.
    Type: Application
    Filed: April 15, 2013
    Publication date: September 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Wendy M. Blanda, Patrick M. Hughes, Peter C. Baciu
  • Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction
    Publication number: 20130236526
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
    Type: Application
    Filed: April 22, 2013
    Publication date: September 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Glenn T. Huang, James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Larry A. Wheeler, Rosy Sheng
  • Alpha-2 agonist polymeric drug delivery systems
    Patent number: 8529927
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 10, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Lon T. Spada, Wendy M. Blanda, Werhner C. Orilla, James A. Burke, Patrick M. Hughes
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 8512738
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as posterior ocular conditions.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Joan-En Chang-Lin, Jane Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Sustained release intraocular implants and methods for treating ocular vasculopathies
    Patent number: 8506986
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: August 13, 2013
    Assignee: Allergan, Inc.
    Inventors: Glenn T Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn